Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (5529)	4/18/2013 8:41:19 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

I would suspect we're both oversold, and being manipulated by forces that individual investor's can't counter. It's known that in the last quarter, on roughly 2 weeks of sales, $19 million worth of T-DM1 was sold. I believe by the next quarter we'll be into the hundreds of millions in sales, perhaps half a billion or more. I believe the royalty, and perhaps milestones, earned at that time will send the stock price to new 52 week highs at that time, but Institutions will own many more shares as frustrated individual investors sell out. I believe that IMGN's earnings will climb dramatically each quarter for the foreseeable future as use of T-DM1 expands first on anecdotal evidence of efficacy in many patients with Her2 positive cancers, other than breast cancer, and finally with it's approval in a wide variety of cancers and expansion in breast cancer to something around $10 billion annually in breast cancer alone. IMGN's earnings from this drug alone could grow to somewhere between half a billion and a billion, or roughly $5 to $10 a share. If other costs are offset by revenue for other partners drugs advancing, and perhaps approvals, a P/E of 10 to 30 ought to be expected with 30 or more very possible if other drug approvals are anticipated. T-DM1 has already proven to be the vehicle that escalated the terms and royalty rates in newer partnerships so IMGN could see far greater earnings from comparable sales of other partners drugs, and even more for drugs developed internally, whether partnered, or not. In short, in time, IMGN will be a major earnings play, much like AMGN was in the 1990's when it split a total of 48 to 1. I note that AMGN has now moved above $100 and wouldn't be surprised if they split in the not to distant future, though it's possible they'll follow the likes of Apple, Google, etc that don't split as stock prices rise to the point that most investors are hard pressed to buy substantial share quantities. As always, JMHO. Gary